Iterum Therapeutics Wins FDA Approval for First-Ever Oral Penem to Treat UTIs
Portfolio Pulse from Benzinga Newsdesk
Iterum Therapeutics has received FDA approval for ORLYNVAH™, the first-ever oral penem for treating uncomplicated urinary tract infections (uUTIs). This marks the first FDA-approved product for Iterum, targeting specific bacteria in adult women with limited treatment options.
October 28, 2024 | 9:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iterum Therapeutics' ORLYNVAH™ receives FDA approval, marking a significant milestone as the first oral penem for uUTIs and the company's first FDA-approved product.
The FDA approval of ORLYNVAH™ is a major milestone for Iterum Therapeutics as it is their first FDA-approved product. This approval could lead to increased investor confidence and potential market expansion, positively impacting the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100